Xiang, G., Huang, Y., Zhang, N., Du, X., Wu, Y., Gan, L., . . . Liu, Y. (2024, November 23). First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. Clinical Medicine Insights: Oncology, 1-12.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Xiang, Guiyuan, Yueyue Huang, Ni Zhang, Xinyu Du, Yuanlin Wu, Lanlan Gan, Yanping Li, Tingting Jiang, and Yao Liu. "First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis."
Clinical Medicine Insights: Oncology 23 Nov. 2024: 1-12.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Xiang, Guiyuan, et al. "First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis."
Clinical Medicine Insights: Oncology, 23 Nov. 2024, pp. 1-12.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.